Amneal Pharmaceuticals Inc (NASDAQ: AMRX) kicked off on Thursday, up 2.51% from the previous trading day, before settling in for the closing price of $7.18. Over the past 52 weeks, AMRX has traded in a range of $5.18-$9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 11.64%. While this was happening, its average annual earnings per share was recorded 17.24%. With a float of $137.45 million, this company’s outstanding shares have now reached $309.88 million.
The extent of productivity of a business whose workforce counts for 8300 workers is very important to gauge. In terms of profitability, gross margin is 36.52%, operating margin of 8.92%, and the pretax margin is -1.97%.
Amneal Pharmaceuticals Inc (AMRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Amneal Pharmaceuticals Inc is 56.14%, while institutional ownership is 36.61%. The most recent insider transaction that took place on Apr 01 ’25, was worth 664,000. In this transaction Director of this company sold 80,000 shares at a rate of $8.30, taking the stock ownership to the 1,728,886 shares. Before that another transaction happened on Mar 14 ’25, when Company’s 10% Owner sold 5,000,000 for $8.35, making the entire transaction worth $41,750,000. This insider now owns 48,578,209 shares in total.
Amneal Pharmaceuticals Inc (AMRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 17.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.91% during the next five years compared to 32.70% growth over the previous five years of trading.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Trading Performance Indicators
Take a look at Amneal Pharmaceuticals Inc’s (AMRX) current performance indicators. Last quarter, stock had a quick ratio of 0.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.83. Likewise, its price to free cash flow for the trailing twelve months is 9.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.80 in one year’s time.
Technical Analysis of Amneal Pharmaceuticals Inc (AMRX)
The latest stats from [Amneal Pharmaceuticals Inc, AMRX] show that its last 5-days average volume of 1.99 million was superior to 1.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 55.20%. Additionally, its Average True Range was 0.38.
During the past 100 days, Amneal Pharmaceuticals Inc’s (AMRX) raw stochastic average was set at 27.42%, which indicates a significant decrease from 35.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.03% in the past 14 days, which was higher than the 36.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.15, while its 200-day Moving Average is $8.14. Now, the first resistance to watch is $7.51. This is followed by the second major resistance level at $7.65. The third major resistance level sits at $7.90. If the price goes on to break the first support level at $7.11, it is likely to go to the next support level at $6.86. Assuming the price breaks the second support level, the third support level stands at $6.72.
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) Key Stats
The company with the Market Capitalisation of 2.31 billion has total of 309,966K Shares Outstanding. Its annual sales at the moment are 2,794 M in contrast with the sum of -116,890 K annual income. Company’s last quarter sales were recorded 730,520 K and last quarter income was -31,080 K.
